Around 350 million people across the world suffer from arthritis, with over 54 million Americans in that group. Treating arthritis costs at least $81 billion each year. It's not surprising that three of the five top-selling drugs in the world in 2017 treated at least one type of arthritis.
But the enormous market for arthritis drugs and treatments extends well beyond those three best-selling drugs. Many of the world's largest biopharmaceutical companies market arthritis drugs and treatments.
Continue Reading Below
Keith Speights owns shares of AbbVie, Celgene, and Pfizer. The Motley Fool owns shares of and recommends Celgene and Johnson & Johnson. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy.